ASH 2020 | Predicting outcomes with WGS in multiple myeloma
Mehmet Samur, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the analysis of whole-genome sequencing (WGS) data from a 2009 study (NCT01191060) of multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone (RVD) alone or RVD followed by autologous stem cell transplantation (ASCT). A genomic scar score (GSS) was calculated for each member of the study cohort and used as a marker to identify clusters associated with specific outcomes. Patients with a low GSS score and a chromosome 9 gain had more positive outcomes when compared to the rest of the participants. This subgroup of patients was also found to have better post-ASCT outcomes. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
